List view / Grid view
2 April 2015 | By Victoria White
PeptiDream Inc. has announced that Novartis has exercised its option to obtain a nonexclusive license to the Peptide Discovery Platform System technology...
31 March 2015 | By Victoria White
Norvatis and Aduro have entered an alliance that is focused on the discovery of cancer immunotherapies and launched a new immuno-oncology research group...
24 March 2015 | By Victoria White
Semma, a company developing cell therapy for T1D, announces that it has closed a $44 million Series A consisting of equity financing and strategic funding...
9 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab)...
5 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV)...
7 May 2014 | By Kevin V. Morris, Bhupinder Bhullar
In this Genomics In-Depth Focus: Kevin V. Morris discusses the therapeutic potential of RNA directed epigenetic regulation of transcription, and Bhupinder Bhullar looks at drug resistance mechanisms and target selection in disease treatment strategies...
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
29 October 2013 | By
Executive Director, Integrated Lead Discovery Head, Novartis
